Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation systems, and medication inventory optimization and tracking systems; hemodynamic monitoring systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
Financial Dynamics | Becton Dickinson reports mixed Q3 results, with EPS beat offset by sales shortfall. Management adjusts organic growth forecast, reflecting market realities. |
Strategic Expansion | Explore the impact of Becton Dickinson's acquisition of Edwards Critical Care, potentially adding $0.36 to annual EPS and strengthening market position. |
Global Market Challenges | Delve into BDX's navigation of international markets, particularly the headwinds in China, and its implications for the company's global growth strategy. |
Future Projections | Analysts estimate BDX's EPS at $13.10 for FY1 and $14.31 for FY2, with management projecting 10% EPS growth and 25%+ margins for FY2025. |
Metrics to compare | BDX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBDXPeersSector | |
---|---|---|---|---|
P/E Ratio | 37.6x | 18.5x | −0.7x | |
PEG Ratio | 2.03 | 0.12 | 0.00 | |
Price/Book | 2.5x | 2.9x | 2.6x | |
Price / LTM Sales | 3.2x | 3.0x | 3.2x | |
Upside (Analyst Target) | 23.4% | 16.5% | 43.2% | |
Fair Value Upside | Unlock | 2.7% | 6.8% | Unlock |